Browsing Molecular Pathology by author "Huang, Paul"
Now showing items 61-66 of 66
-
The perplexing role of immuno-oncology drugs in osteosarcoma.
Smrke, A; Tam, YB; Anderson, PM; Jones, RL; Huang, PH (ELSEVIER, 2021-12-01)Osteosarcoma is a rare, primary tumour of bone. Curative treatment consists of multi-agent chemotherapy and complete surgical resection. Despite the use of multi-agent chemotherapy, the risk of recurrence is high. Survival ... -
Three-dimensional modelling identifies novel genetic dependencies associated with breast cancer progression in the isogenic MCF10 model.
Maguire, SL; Peck, B; Wai, PT; Campbell, J; Barker, H; et al. (WILEY, 2016-11-01)The initiation and progression of breast cancer from the transformation of the normal epithelium to ductal carcinoma in situ (DCIS) and invasive disease is a complex process involving the acquisition of genetic alterations ... -
Translational Aspects of Epithelioid Sarcoma: Current Consensus.
Grünewald, TGP; Postel-Vinay, S; Nakayama, RT; Berlow, NE; Bolzicco, A; et al. (AMER ASSOC CANCER RESEARCH, 2024-03-15)Epithelioid sarcoma (EpS) is an ultra-rare malignant soft-tissue cancer mostly affecting adolescents and young adults. EpS often exhibits an unfavorable clinical course with fatal outcome in ∼50% of cases despite aggressive ... -
Tropomyosin receptor kinase inhibitors in the management of sarcomas.
Wilding, CP; Loong, HH; Huang, PH; Jones, RL (LIPPINCOTT WILLIAMS & WILKINS, 2020-06-05)PURPOSE OF REVIEW: Genetic aberrations resulting in tropomyosin receptor kinase (TRK) fusion proteins can drive oncogenesis and are postulated to occur in up to 1% of solid tumours. However, TRK fusions in adult sarcomas ... -
Unmet Medical Needs and Future Perspectives for Leiomyosarcoma Patients-A Position Paper from the National LeioMyoSarcoma Foundation (NLMSF) and Sarcoma Patients EuroNet (SPAEN).
Kasper, B; Achee, A; Schuster, K; Wilson, R; van Oortmerssen, G; et al. (MDPI, 2021-02-20)As leiomyosarcoma patients are challenged by the development of metastatic disease, effective systemic therapies are the cornerstone of outcome. However, the overall activity of the currently available conventional systemic ... -
Virtual Biopsy in Soft Tissue Sarcoma. How Close Are We?
Arthur, A; Johnston, EW; Winfield, JM; Blackledge, MD; Jones, RL; et al. (FRONTIERS MEDIA SA, 2022-07-01)A shift in radiology to a data-driven specialty has been unlocked by synergistic developments in imaging biomarkers (IB) and computational science. This is advancing the capability to deliver "virtual biopsies" within ...